-
Product Insights
Ewing Sarcoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Ewing Sarcoma Clinical Trial Report Overview A total of 434 Ewing Sarcoma clinical trials were conducted as of February 2024. The Ewing Sarcoma clinical trial report provides a comprehensive understanding of the Ewing Sarcoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       North America ·       ...
-
Product Insights
Ewing Sarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ewing Sarcoma - Drugs In Development, 2023’, provides an overview of the Ewing Sarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ewing Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Sector Analysis
Ewing Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Ewing Sarcoma Marketed and Pipeline Drugs Report Overview Ewing sarcoma (ES) is an aggressive tumor of adolescents and young adults that constitutes 10% to 15% of all bone sarcomas. The disease is named after James Ewing, who first described it in 1921. These sarcomas originate from unique mesenchymal progenitor cells due to their similar histologic and immunohistochemical characteristics. The most common anatomical sites include the pelvis, axial skeleton, and femur; however, it may occur in almost any bone or soft...